Concepedia

Author

David Hermann

Research Triangle Park Foundation

Also Known As

D. J. B. Hermann, D. J. HERMANN, D. J. Hermann, D.J. HERMANN, D.J. Hermann, D. J. Hermann, DAVID J. HERMANN, David Hermann, David J Hermann, David J. Hermann

63

Publications

5K

Citations

26

H-Index

83

Concepts

All Affiliations

Research Triangle Park FoundationGates FoundationCritical Path InstituteStanford UniversityUniversity of North Carolina at Chapel Hill
DH

About

David Hermann is an author at Research Triangle Park Foundation specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

13

14

1.2K

2

Health Sciences

2

2

112

3

Arts

1

1

49

4

Engineering

1

1

50

5

Public Health

1

1

351

David Hermann

×

34

Publications

4.6K

Citations

24

H-Index

YearCitations

Influence of Age and Gender on the Pharmacokinetics and Pharmacodynamics of Remifentanil

Charles F. Minto, Thomas W. Schnider, Talmage D. Egan,

Anesthesiology

1997

1.2K

The Pharmacokinetics of the New Short-acting Opioid Remifentanil (GI87084B) in Healthy Adult Male Volunteers

Talmage D. Egan, Harry J. M. Lemmens, Pierre Fiset,

Anesthesiology

1993

627

Marked Suppression of Dihydrotestosterone in Men with Benign Prostatic Hyperplasia by Dutasteride, a Dual 5α-Reductase Inhibitor

Richard V. Clark, David Hermann, Glenn R. Cunningham,

The Journal of Clinical Endocrinology & Metabolism

2004

455

Remifentanil Versus Alfentanil

Talmage D. Egan, Charles F. Minto, David Hermann,

Anesthesiology

1996

419

Measured Context-sensitive Half-times of Remifentanil and Alfentanil

Atul Kapila, Peter S. A. Glass, James Jacobs,

Anesthesiology

1995

405

A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis

Marjorie Z. Imperial, Payam Nahid, Patrick Phillips,

Nature Medicine

2018

351

Unique Preclinical Characteristics of GG745, A Potent Dual Inhibitor of 5AR

H. Neal Bramson, David Hermann, Kenneth W. Batchelor,

Journal of Pharmacology and Experimental Therapeutics

1997

150

Influence of Age and Gender on the Pharmacokinetics and Pharmacodynamics of Remifentanil

Charles F. Minto, Thomas W. Schnider, Talmage D. Egan,

Survey of Anesthesiology

1997

92

Determination of the Potency of Remifentanil Compared with Alfentanil Using Ventilatory Depression as the Measure of Opioid Effect

Peter S. A. Glass, Irène A. Iselin-Chaves, David K. Goodman,

Anesthesiology

1999

75

DG-041 inhibits the EP3 prostanoid receptor—A new target for inhibition of platelet function in atherothrombotic disease

Stan Heptinstall, David Iyú, Panagiotis Manolopoulos,

Platelets

2008

68

Page 1